Next, we excluded 10 duplicate trials, 7 trials that did not involve PD-1 antibody therapy, 1 trial that was not related to tumor therapy, 22 observational trials, and 12 trials that did not meet the inclusion age requirements. This evidence concerns the gene PDCD1 and neoplasm.